1. To update Section 1 Introduction with safety results from Phase II studies in DMD boys (VBP15-002 and VBP15-003) 2. To update Section 1.5 Overall Benefit/Risk 3. To update Section 13 References 4. To clarify that dose may be escalated incrementally to 6.0 mg/kg/day 5. To clarify the circumstances under which study drug dose should be interrupted, de-escalated, or discontinued 6. To allow dose de-escalation from 6.0 mg/kg/day to 2.0 mg/kg/day to be followed by dose escalation to 4.0 mg/kg/day,balancing efficacy and safety concerns, in the opinion of the Investigator 7. To prohibit use of Exondys 51, Translarna, and other medications indicated for treatment of DMD during the study 8. To add details of Data and Safety Monitoring Board (DSMB) responsibilities 9. To add collection of 8.5 mL of blood at the Month 24 Visit for deoxyribonucleic acid (DNA) testing for established genetic modifiers of DMD 10. To add spine x-ray for detection of fracture at the Month 24 Visit 11. To add hand x-ray for assessment of bone age at the Month 24 Visit 12. To remove the designation of BMI z-score as the primary safety outcome 13. To update the primary efficacy endpoint 14. To remove comparison of vamorolone with prednisone-treated historical control data for serum PD biomarkers of safety 15. To add comparison of vamorolone to prednisone- and deflazacort-treated historical control data for bone age, spine fracture, and height z-score, and comparison to deflazacort-treated historical control data for BMI z-score 16. To update the statistical methodology and composition of the control populations 17. To clarify that collection of the Pediatric Outcomes Data Collection Instrument (PODCI) does not need to be repeated at the VBP15-LTE Baseline Visit if the Baseline Visit occurs ≤ 28 days after the date of the VBP15-003 Week 24 Visit 18. To clarify the PD biomarkers to be evaluated